Blueprint Medicines Corp (NASDAQ:BPMC) CEO Jeffrey W. Albers sold 20,000 shares of the firm’s stock in a transaction dated Monday, November 5th. The stock was sold at an average price of $63.49, for a total value of $1,269,800.00. Following the transaction, the chief executive officer now directly owns 20,000 shares in the company, valued at approximately $1,269,800. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
BPMC stock opened at $63.29 on Friday. Blueprint Medicines Corp has a 12-month low of $57.44 and a 12-month high of $109.00. The company has a quick ratio of 10.05, a current ratio of 10.05 and a debt-to-equity ratio of 0.03.
Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings results on Tuesday, October 30th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.57) by ($0.09). Blueprint Medicines had a negative net margin of 455.15% and a negative return on equity of 36.72%. The company had revenue of $1.10 million for the quarter, compared to analyst estimates of $1.87 million. During the same quarter in the previous year, the business posted ($0.96) earnings per share. Blueprint Medicines’s revenue was down 86.4% on a year-over-year basis. As a group, equities analysts forecast that Blueprint Medicines Corp will post -5.25 EPS for the current year.
BPMC has been the topic of a number of research reports. ValuEngine raised Blueprint Medicines from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 2nd. Wedbush restated an “outperform” rating and issued a $101.00 price objective on shares of Blueprint Medicines in a research report on Monday, October 8th. Zacks Investment Research downgraded shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research report on Friday, November 2nd. Leerink Swann started coverage on shares of Blueprint Medicines in a research report on Tuesday, September 25th. They issued an “outperform” rating and a $105.00 price objective for the company. Finally, BidaskClub upgraded shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, August 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $97.14.
About Blueprint Medicines
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Further Reading: Stock Selection – What is cash flow?
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.